Crescent Biopharma, Inc. · NASDAQ:CBIO
Crescent Biopharma — Glycomimetics — Merger or Acquisition (April 2025)
27 slides from Crescent Biopharma's merger presentation, Apr 3, 2025
Slide 1: Crescent Biopharma Overview
April 2025 Crescent Biopharma Overview
Slide 2: Disclaimers
2 Disclaimers This presentation is for informational purposes only and only a summary of certain information related to Crescent Biopharma, Inc. (“we”, “Crescent” or the “Company”). It does not purport to be complete and does not contain all information that an investor may need to consider in makin
Slide 3: Crescent Biopharma aims to advance the next wave of innovation in cancer therapy
3 Crescent Biopharma aims to advance the next wave of innovation in cancer therapy 1. Anticipated expiration for filed provisional patent is 2045+ 2. Financing scheduled to close immediately prior to the closing of the merger with GlycoMimetics Notes: NSCLC: Non-small cell lung cancer. MoA: Mechanis
Slide 4: Crescent is advancing three highly impactful oncology programs with best-in-class potential
4 Crescent is advancing three highly impactful oncology programs with best-in-class potential Notes: bsAb: Bispecific antibody. IND: Investigational New Drug application. PoC: Proof-of-concept CR-001 PD-1 x VEGF cooperative tetravalent bsAb Same MoA as ivonescimab Designed to reproduce ivonescimab’s
Slide 5: Multiple ways to win: Crescent pipeline enables optionality with differentiating combination therapies
5 Multiple ways to win: Crescent pipeline enables optionality with differentiating combination therapies Optimized Novel Monotherapies Synergistic Combination Approaches CR-001 CR-002 CR-003 CR-001 + CR-002 CR-001 + CR-003 Engineered for: Best-in-class efficacy Efficacy across histologies Pharmacoki
Slide 6: Crescent leverages three key advances in oncology for next-generation combinations
6 Crescent leverages three key advances in oncology for next-generation combinations within unique portfolio EVOLUTION OF CHEMOTHERAPY Enhanced efficacy & safety via cooperativity Enhanced efficacy & safety via targeting ADC PD-(L)1 Cooperative bispecific PD-1 x VEGF EVOLUTION OF IMMUNO-ONCOLOGY Sys
Slide 7: PD-(L)1-targeted therapies, annualizing $50B+, have transformed oncology
7 PD-(L)1-targeted therapies, annualizing $50B+, have transformed oncology – with Keytruda now the best-selling drug in the world 1. 5-year follow-up demonstrated mOS of 22.0 vs 10.6 months. Notes: 1L: First-line. NSQ: Non-squamous. NSCLC: Non-small cell lung cancer. mOS: median overall survival. NR
Slide 8: Ivonescimab doubled progression-free survival vs. Keytruda in a P3 NSCLC trial
8 Ivonescimab, a cooperative PD-1 x VEGF bispecific, doubled progression-free survival vs. Keytruda in a P3 NSCLC trial Notes: HR: hazard ratio. PFS: progression-free survival. AE: adverse event. NSQ: Non-squamous SQ: Squamous. ORR: Objective response rate. Akeso Biopharma has licensed ivonescimab t
Slide 9: CR-001 is one of few programs designed to exhibit ivonescimab-like cooperative pharmacology
9 CR-001 is one of the few programs intentionally designed to exhibit ivonescimab-like cooperative pharmacology Sources: Internal data; Summit Therapeutics 2023 SITC Poster; BioNTech 2024 ESMO Presentation; LaNova patent filings; Various patent filings; 2017 Lee (Scientific Reports); 2007 Rudge (PNA
Slide 10: CR-001 Cooperative, tetravalent PD-1 x VEGF bispecific antibody
10 CR-001 Cooperative, tetravalent PD-1 x VEGF bispecific antibody
Slide 11: Ivonescimab's novel, cooperative MoA is hypothesized to drive enhanced anti-tumor activity
11 Ivonescimab’s novel, cooperative MoA is hypothesized to drive enhanced anti-tumor activity while maintaining tolerability Sources: 2023 Zhong (SITC Poster); Summit Therapeutics VEGF drives tumor angiogenesis PD-L1 expression suppresses T cells Tumor Microenvironment (TME) VEGF PD-L1 PD-1 Tumor Ce
Slide 12: CR-001 is a highly potent PD-1 x VEGF bsAb designed to recapitulate ivonescimab
12 CR-001 is a highly potent PD-1 x VEGF bsAb designed to recapitulate ivonescimab’s cooperative pharmacology Notes: IgG: Immunoglobulin G. scFvs: Single-chain variable fragment. ADCC: Antibody-dependent cell-mediated cytotoxicity; PK: Pharmacokinetics. FcRn: Neonatal Fc receptor. CR-001 Same design
Slide 13: CR-001 replicates ivonescimab's cooperative binding effect
13 CR-001 replicates ivonescimab’s cooperative binding effect which leads to cooperative inhibition of PD-1 signaling in presence of VEGF Notes: Ivonescimab generated internally based on published sequence. PD-1 / PD-L1 signaling inhibition measured in RLU (relative light units), a measure of lumine
Slide 14: CR-001 engineering replicates ivonescimab function with biophysical properties
14 CR-001 engineering replicates ivonescimab function with biophysical properties that maximize flexibility in development Notes: CDR: Complementarity-determining region. CDC: Complement-dependent cytotoxicity. Fc: Fragment crystallizable. Ivonescimab’s unique structure and geometry – and Standard m
Slide 15: CR-001 has potential to transform SoC across a multitude of oncology indications
15 CR-001 has potential to transform SoC across a multitude of oncology indications, with numerous first-in-class opportunities Notes: EGFRm = mutant epidermal growth factor receptor. Sources: Keytruda Label; Opdivo Label; Tecentriq Label; Imfinzi Label; Libtayo Label; Bavencio Label; Jemperli Label
Slide 16: Development programs across key late-stage competitors include numerous P3s
16 Development programs across key late-stage competitors include numerous P3s with PFS & OS readouts, paving the way for CR-001 Notes: List of trials not exhaustive; BNT327-06 is a master protocol for two P2/3 sub-studies; BNT327 P2/3 in NSCLC announced Nov 2024 but details not yet available; PFS a
Slide 17: Two parallel development paths for CR-001
17 TWO PARALLEL DEVELOPMENT PATHS FOR CR-001 Parallel clinical development paths offer potential for both first-in-class and lower risk opportunities for CR-001 First-in-class opportunities Numerous indications with clinically meaningful anti-PD-(L)1 +/- VEGF efficacy and potential to combine with c
Slide 18: CR-001 Phase 1 data offer potential for early acceleration
18 CR-001 Phase 1 data offer potential for early acceleration – a rarity for a solid tumor oncology program High conviction in CR-001’s clinical profile can be reached in ~9-12 months from Phase 1 initiation, offering potential for significant early value inflection Phase 1 interim proof-of-concept
Slide 19: CR-001 preclinical data reproduce ivonescimab's breakthrough pharmacology
19 CR-001 preclinical data reproduce ivonescimab’s breakthrough pharmacology & are rapidly advancing to generate significant value Unprecedented third-party data validate PD-1 x VEGF cooperativity Transformative MoA for $50B+ market CR-001’s proprietary engineering is designed to replicate ivonescim
Slide 20: CR-002 & CR-003 Topoisomerase inhibitor ADCs against validated targets
20 CR-002 & CR-003 Topoisomerase inhibitor ADCs against validated targets
Slide 21: CR-002 and CR-003 are potentially best-in-class topoisomerase inhibitor ADCs
21 CR-002 and CR-003 are potentially best-in-class topoisomerase inhibitor ADCs, with applicability across solid tumors Potential to synergize with CR-001 and other immunotherapies Each ADC can be leveraged in combination studies in solid tumors Validated, undisclosed solid tumor ADC targets Targets
Slide 22: ADCs with topoisomerase inhibitor payloads have demonstrated best-in-modality efficacy and safety
22 ADCs with topoisomerase inhibitor payloads have demonstrated best-in-modality efficacy and safety Notes: GEJ: Gastroesophageal junction. A: Approved. R: In registration. PN rates are weighted averages, by number of patients, across indications / trials and include PN, PSN, PMN, and PSMN when sepa
Slide 23: Corporate
23 Corporate
Slide 24: Rapidly growing leadership team with deep experience
24 Susan Moran, M.D. Rapidly growing leadership team with deep experience building the next generation of biotechnology companies Joshua Brumm Chief Executive Officer Jonathan McNeill, M.D. President & Chief Operating Officer Ellie Im, M.D. Chief Medical Officer Rick Scalzo Chief Financial Officer B
Slide 25: Financing expected to fund Crescent programs through key anticipated catalysts
25 Financing expected to fund Crescent programs through key anticipated value-generating catalysts Notes: mNSCLC: Metastatic non-small cell lung cancer. ES: Extensive stage. EGFRm: Mutant EGFR. Sources: ClinicalTrials.gov; Company websites 2025 2026 Current cash expected to fund operations through 2
Slide 26: Estimated capitalization following close of transactions
26 Estimated capitalization following close of transactions Pre-closing financing Shares of common stock outstanding Shares of common stock outstanding Shares of common stock Pre-funded warrants Series A shares 64,532,953 105,137,814 298,298,000 1,339,680,730 273,643,080 Estimated total shares of co
Slide 27: Thank you
Thank you Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the Exchange Act and Section 27A of the Securities Act) concerning GlycoMimetics, Crescent, the proposed transactions and other matters. These forward-looking s